Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
E. Gabriela Chiorean(University of Washington), Andrew L. Coveler(University of Washington)
Cited by 252
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
|The Lancet Oncology|2023|244
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
|Haematologica|2015|121
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
|British Journal of Cancer|2023|30
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).
|Journal of Clinical Oncology|2021|6